Inhibition of NF-κB by (E)3-[(4-methylphenyl)-sulfonyl]-2-propenenitrile (BAY11-7082; BAY) is associated with enhanced 12-O-tetradecanoylphorbol-13-acetate-induced growth suppression and apoptosis in human prostate cancer PC-3 cells

International Journal of Oncology

Volumn 32, Issue 1, 2008, Pages 257-264

  Zheng, Xi ^a   Chang, Richard L ^a   Cui, Xiao Xing ^a   Avila, Gina ^a   Huang, Mou Tuan ^a   Liu, Yue ^a   Kong, Ah Ng Tony ^a   Rabson, Arnold B ^b,c   Conney, Allan H ^a,b  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

12 O tetradecanoylphorbol 13 acetate; Apoptosis; Nuclear factor B; Prostate cancer; Xenograft tumor

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; MATRIGEL; PHORBOL 13 ACETATE 12 MYRISTATE; 3-(4-METHYLPHENYLSULFONYL)-2-PROPENENITRILE; NITRILE; SULFONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN SYNTHESIS INHIBITION; TREATMENT DURATION; ANIMAL; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; HUMANS; MALE; MICE; MICE, NUDE; NF-KAPPA B; NITRILES; PROSTATIC NEOPLASMS; SULFONES; TETRADECANOYLPHORBOL ACETATE;

EID: 38749104632     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.32.1.257     Document Type: Article

References (41)

1. Huberman E and Callaham MF: Induction of terminal differentiation in human promyelocytic leukemia cells by tumor-promoting agents. Proc Natl Acad Sci USA 76: 1293-1297, 1979.
2. Rovera G, O'Brien TG and Diamond L: Induction of differentiation in human promyelocytic leukemia cells by tumor promoters. Science 204: 868-870, 1979.
3. Han ZT, Zhu XX, Yang RY, Sun JZ, Tian GF, Liu X J, Cao GS, Newmark HL, Conney AH and Chang RL: Effect of intravenous infusions of 12-O-tetradecanoylphorbol-13-acetate (TPA) in patients with myelocytic leukemia: preliminary studies on therapeutic efficacy and toxicity. Proc Natl Acad Sci USA 95: 5357-5361, 1998.
4. Strair RK, Schaar D, Goodell L, Aisner J, Chin KV, Eid J, Senzon R, Cui XX, Han ZT, Knox B, Rabson AB, Chang R and Conney A: Administration of a phorbol ester to patients with hematological malignancies: preliminary results from a phase I clinical trial of 12-O-tetradecanoylphorbol-13-acetate. Clin Cancer Res 8: 2512-2518, 2002.
5. Schaar D, Goodell L, Aisner J, Cui XX, Han ZT, Chang R, Martin J, Grospe S, Dudek L, Riley J, Manago J, Lin Y, Rubin EH, Conney A and Strair RK: A phase I clinical trial of 12-O-tetradecanoylphorbol-13-acetate for patients with relapsed/refractory malignancies. Cancer Chemother Pharmacol 57: 789-795, 2006.
6. Zheng X, Chang RL, Cui XX, Kelly KA, Shih WJ, Lin Y, Strair R, Suh J, Han ZT, Rabson A and Conney AH: Synergistic effects of clinically achievable concentrations of 12-0-tetradecanoylphorbol-13-acetate in combination with all-trans retinoic acid. 1 alpha, 25-dihydroxyvitamin D3, and sodium butyrate on differentiation in HL-60 cells. Oncol Res 12: 419-427, 2001.
7. Zheng X, Ryan A, Patel N, Klemons S, Hansson A, Shih WJ, Lin Y, Huberman E, Chang RL and Conney AH: Synergistic stimulatory effect of 12-O-tetradecanoylphorbol-13-acetate and capsaicin on macrophage differentiation in HL-60 and HL-525 human myeloid leukemia cells. Int J Oncol 26: 441-448, 2005.
8. Powell CT, Brittis NJ, Stec D, Hug H, Heston WD and Fair WR: Persistent membrane translocation of protein kinase C alpha during 12-0-tetradecanoylphorbol-13-acetate-induced apoptosis of LNCaP human prostate cancer cells. Cell Growth Differ 7: 419-428, 1996.
9. Garzotto M, White-Jones M, Jiang Y, Ehleiter D, Liao WC, Haimovitz-Friedman A, Fuks Z and Kolesnick R: 12-O-tetradecanoylphorbol-13-acetate-induced apoptosis in LNCaP cells is mediated through ceramide synthase. Cancer Res 58: 2260-2264, 1998.
10. Altuwaijri S, Lin HK, Chuang KH, Lin WJ, Yeh S, Hanchett LA, Rahman MM, Kang HY, Tsai MY, Zhang Y, Yang L and Chang C: Interruption of nuclear factor kappaB signaling by the androgen receptor facilitates 12-O-tetradecanoylphorbolacetate-induced apoptosis in androgen-sensitive prostate cancer LNCaP cells. Cancer Res 63: 7106-7112, 2003.
11. Zheng X, Chang RL, Cui XX, Avila GE, Lee S, Lu YP, Lou YR, Shih W J, Lin Y, Reuhl K, Newmark H, Rabson A and Conney AH: Inhibitory effect of 12-O-tetradecanoylphorbol-13-acetate alone or in combination with all-trans-retinoic acid on the growth of LNCaP prostate tumors in immunodeficient mice. Cancer Res 64: 1811-1820, 2004.
12. Zheng X, Chang RL, Cui XX, Avila GE, Hebbar V, Garzotto M, Shih WJ, Lin Y, Lu SE, Rabson AB, Kong AN and Conney AH: Effects of 12-O-tetradecnoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate cancer LNCaP cells cultured in vitro or grown as xenograft tumors in immunodeficient mice. Clin Cancer Res 12: 3444-3451, 2006.
13. Blagosklonny MV, Dixon SC, Robey R and Figg WD: Resistance to growth inhibitory and apoptotic effects of phorbol ester and UCN-01 in aggressive cancer cell lines. Int J Oncol 18: 697-704, 2001.
14. Palayoor ST, Youmell MY, Calderwood SK, Coleman CN and Price BD: Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene 18: 7389-7394, 1999.
15. Suh J, Payvandi F, Edelstein LC, Amenta PS, Zong WX, Gelinas C and Rabson AB: Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells. Prostate 52: 183-200, 2002.
16. Barkett M and Gilmore TD: Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene 18: 6910-6924, 1999.
17. Baldwin AS: Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 107: 241-246, 2001.
18. Busuttil V, Bottero V, Frelin C, Imbert V, Ricci JE, Auberger P and Peyron JF: Blocking NF-kappaB activation in Jurkat leukemic T cells converts the survival agent and tumor promoter PMA into an apoptotic effector. Oncogene 21: 3213-3224, 2002.
19. Hansson A, Marin YE, Suh J, Rabson AB, Chen S, Huberman E, Chang RL, Conney AH and Zheng X: Enhancement of TPA-induced growth inhibition and apoptosis in myeloid leukemia cells by BAY 11-7082, an NF-κB inhibitor. Int J Oncol 27: 941-948, 2005.
20. Xu C, Shen G, Chen C, Gelinas C and Kong AN: Suppression of NF-kappaB and NF-kappaB-regulated gene expression by sulforaphane and PEITC through IkappaBalpha, IKK pathway in human prostate cancer PC-3 cells. Oncogene 24: 4486-4495, 2005.
21. Hsu JC: Multiple Comparisons: Theory and Methods. Chapman and Hall, New York, 1996.
22. Pilat MJ, Kamradt JM and Pienta KJ: Hormone resistance in prostate cancer. Cancer Metastasis Rev 17: 373-381, 1998.
23. So A, Gleave M, Hurtado-Col A and Nelson C: Mechanisms of the development of androgen independence in prostate cancer. World J Urol 23: 1-9, 2005.
24. Raghavan D, Koczwara B and Javle M: Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer. Eur J Cancer 33: 566-574, 1997.
25. Morris MJ and Scher HI: Novel therapies for the treatment of prostate cancer: current clinical trials and development strategies. Surg Oncol 11: 13-23, 2002.
26. Garzotto M, Haimovitz-Friedman A, Liao WC, White-Jones M, Huryk R, Heston WD, Cardon-Cardo C, Kolesnick R and Fuks Z: Reversal of radiation resistance in LNCaP cells by targeting apoptosis through ceramide synthase. Cancer Res 59: 5194-5201, 1999.
27. Lessard L, Mes-Masson AM, Lamarre L, Wall L, Lattouf JB and Saad F: NF-kappa B nuclear localization and its prognostic significance in prostate cancer. BJU Int 91: 417-420, 2003.
28. Ross JS, Kallakury BV, Sheehan CE, Fisher HA, Kaufman RP Jr, Kaur P, Gray K and Stringer B: Expression of nuclear factor-kappa B and 1 kappa B alpha proteins in prostatic adenocarcinomas: correlation of nuclear factor-kappa B immunoreactivity with disease recurrence. Clin Cancer Res 10: 2466-2472, 2004.
29. Shukla S, MacLennan GT, Fu P, Patel J, Marengo SR, Resnick MI and Gupta S: Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. Neoplasia 6: 390-400, 2004.
30. Fradet V, Lessard L, Begin LR, Karakiewicz P, Masson AM and Saad F: Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer. Clin Cancer Res 10: 8460-8464, 2004.
31. Keller SA, Schattner EJ and Cesarman E: Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood 96: 2537-2542, 2000.
32. Hu X, Janssen WE, Moscinski LC, Bryington M, Dangsupa A, Rezai-Zadeh N, Babbin BA and Zuckerman KS: An IkappaBalpha inhibitor causes leukemia cell death through a p38 MAP kinase-dependent, NF-kappaB-independent mechanism. Cancer Res 61: 6290-6296, 2001.
33. Shimada K, Nakamura M, Ishida E, Kishi M, Yonehara S and Konishi N: Contributions of mitogen-activated protein kinase and nuclear factor kappa B to N-(4-hydroxyphenyl)retinamide-induced apoptosis in prostate cancer cells. Mol Carcinog 35: 127-137, 2002.
34. Dewan MZ, Terashima K, Taruishi M, Hasegawa H, Ito M, Tanaka Y, Mori N, Sata T, Koyanagi Y, Maeda M, Kubuki Y, Okayama A, Fujii M and Yamamoto N: Rapid tumor formation of human T-cell leukemia viras type 1-infected cell lines in novel NOD-SCID/gammac(null) mice: suppression by an inhibitor against NF-kappaB. J Virol 77: 5286-5294, 2003.
35. Ayala GE, Dai H, Ittmann M, Li R, Powell M, Frolov A, Wheeler TM, Thompson TC and Rowley D: Growth and survival mechanisms associated with perineural invasion in prostate cancer. Cancer Res 64: 6082-6090, 2004.
36. Pierce JW, Schoenleber R, Jesmok G, Best J, Moore SA, Collins T and Gerritsen ME: Novel inhibitors of cytokine-induced Ikappa-Balpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflanunatory effects in vivo. J Biol Chem 272: 21096-21103, 1997.
37. Domingo-Domenech J, Oliva C, Rovira A, Codony-Servat J, Bosch M, Filella X, Montagut C, Tapia M, Campas C, Dang L, Rolfe M, Ross JS, Gascon P, Albanell J and Mellado B: Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin Cancer Res 12: 5578-5586, 2006.
38. Camp ER, Li J, Minnich DJ, Brank A, Moldawer LL, MacKay SL and Hochwald SN: Inducible nuclear factor-kappaB activation contributes to chemotherapy resistance in gastric cancer. J Am Coll Surg 199: 249-258, 2004.
39. Wang HE, Wu HC, Kao S J, Tseng FW, Wang YS, Yu HM, Chou SL, Yen SH and Chi KH: Modulation of 5-fluorouracil cytotoxicity through thymidylate synthase and NF-kappaB down-regulation and its application on the radiolabelled iododeoxyuridine therapy on human hepatoma cell. Biochem Pharmacol 69: 617-626, 2005.
40. Hohmann HP, Remy R, Scheidereit C and van Loon AP: Maintenance of NF-kappa B activity is dependent on protein synthesis and the continuous presence of external stimuli. Mol Cell Biol 11: 259-266, 1991.
41. Pennington KN, Taylor JA, Bren GD and Paya CV: IkappaB kinase-dependent chronic activation of NF-kappaB is necessary for p21 (WAF1/Cip1) inhibition of differentiation-induced apoptosis of monocytes. Mol Cell Biol 21: 1930-1941, 2001.